SymbioCellTech raises $2.5M seed funding

Written By Travis Manning

SymbioCellTech (SCT) raised $2.5M from H2M Capital Partners and angel investors. This is the second seed-stage round of funding for SCT. To date, the company has raised over $5.6M towards the development of its novel technologies for the cure of insulin-dependent diabetes mellitus.

Travis Manning https://www.symbiocelltech.com
Previous

SCT Files New Patent for the Cure of Type-1 Diabetes
Next

JDCA Highlights SymbioCellTech as a company developing a practical cure